Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000824 · ClinicalTrials.gov registry record · NA
A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- NA
- Development phase
NCT00000824 is a NA study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID).
The verdict
NCT00000824, a NA study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- NA
- Development phase
Study Summary
To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.
Interventions
- DRUG Lymphocytes, Activated
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000824
The ClinicalTrials.gov registry entry for NCT00000824 describes a study currently listed as terminated, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lymphocytes, Activated is the first listed.
NCT00000824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000824 about?
NCT00000824 is a clinical study titled "A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients". To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV. With lower CD4 counts, HIV-infected patients may not be...
What is the current status of trial NCT00000824?
This trial is currently terminated. It is a NA study. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00000824?
The interventions under investigation include: Lymphocytes, Activated (DRUG).
Who is sponsoring clinical trial NCT00000824?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.